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Abstract
Background: Systematic reviews with meta-analyses often contain many statistical tests. This multiplicity may increase the
risk of type I error. Few attempts have been made to address the problem of statistical multiplicity in systematic reviews.
Before the implications are properly considered, the size of the issue deserves clarification. Because of the emphasis on bias
evaluation and because of the editorial processes involved, Cochrane reviews may contain more multiplicity than their non-
Cochrane counterparts. This study measured the quantity of statistical multiplicity present in a population of systematic
reviews and aimed to assess whether this quantity is different in Cochrane and non-Cochrane reviews.
Methods/Principal Findings: We selected all the systematic reviews published by the Cochrane Anaesthesia Review Group
containing a meta-analysis and matched them with comparable non-Cochrane reviews. We counted the number of
statistical tests done in each systematic review. The median number of tests overall was 10 (interquartile range (IQR) 6 to
18). The median was 12 in Cochrane and 8 in non-Cochrane reviews (difference in medians 4 (95% confidence interval (CI)
2.0–19.0). The proportion that used an assessment of risk of bias as a reason for doing extra analyses was 42% in Cochrane
and 28% in non-Cochrane reviews (difference in proportions 14% (95% CI 28 to 36). The issue of multiplicity was addressed
in 6% of all the reviews.
Conclusion/Significance: Statistical multiplicity in systematic reviews requires attention. We found more multiplicity in
Cochrane reviews than in non-Cochrane reviews. Many of the reasons for the increase in multiplicity may well represent
improved methodological approaches and greater transparency, but multiplicity may also cause an increased risk of
spurious conclusions. Few systematic reviews, whether Cochrane or non-Cochrane, address the issue of multiplicity.
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Introduction
Background
A systematic review aims to collate all the available evidence in
order to answer a specific research question. Meta-analysis refers
to the statistical combining of results. Systematic review with meta-
analysis has the potential to increase the power to assess the
efficacy of an intervention [1]. Anaesthesia is one specialty where
this increase in power may be particularly useful; important
outcomes - such as mortality and severe morbidity - are often rare
[2,3] and increased precision is therefore valuable.
In order to benefit most from this increased precision, we need
to strive to make conclusions in systematic reviews as reliable as
possible. There are many methodological challenges in this
endeavour. For example, consideration must be given to several
types of risk of bias (‘systematic errors’), duplicate publication,
heterogeneity and inclusion of outdated studies [4–6]. ‘Statistical
multiplicity’ refers to the presence of more than one test of a null
hypothesis and it creates another challenge when trying to ensure
the reliability of conclusions.
There are various reasons why multiple statistical tests may be
done in a systematic review: multiple outcomes may be
compared, the same outcome may be measured at different time
points, there may be multiple intervention groups, there may be
analyses made of subgroups, or accumulating data may be
compared repeatedly over time. Statistical multiplicity is a
problem because it increases the risk of type 1 error [7,8]. Type
1 error occurs when the null hypothesis is incorrectly rejected;
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group of two or more statistical tests, and significance is declared
for any one test if the P-value is less than 0.05, then the
probability of making an error overall ends up being higher than
5%. In practical terms, statistical multiplicity increases the risk for
false positive findings [9,10].
The fact that multiple statistical tests increase the risk of type 1
error is clear. The importance of this increase in risk, and whether
adjustments should be made, is far less clear. Published opinions -
in the context of single trials - vary enormously. Some argue that
any adjustment for multiplicity is entirely unnecessary [11,12],
while others contend that adjustments should always be done
when there is more than one test [13–15]. Many suggest a
variation of a middle ground, with various interpretations of when
and how adjustments should be made [9,16].
While the issue of statistical multiplicity has been keenly debated
in the context of single trials, it has received little attention in the
context of systematic reviews. Authors of systematic reviews often
aim to cover a topic thoroughly, sometimes with many planned
outcomes, subgroups and sensitivity analyses. There is therefore
good reason for statistical multiplicity to be common in systematic
reviews. In the reviews themselves, the presence of multiplicity is
rarely mentioned [17]. A recent review on the topic of multiple
comparisons in systematic reviews concluded that the issue
requires recognition and further research is required [10]. The
Cochrane Collaboration (TCC) is an international organization
that prepares, maintains and promotes systematic reviews [18].
From within this organisation, the issue of multiple comparisons in
systematic reviews has begun to receive attention [10,19,20]. But
this attention has so far been limited.
The issue of statistical multiplicity in systematic reviews is
complex and challenging. In a systematic review, a null hypothesis
is tested using meta-analysis. That same null hypothesis may have
been tested previously, individually, in the trials included in the
meta-analysis. In this case, one could argue that the results do not
represent any increased multiplicity. Instead, one might argue that a
meta-analysis provides a summary of the multiplicity that already
existed. Others might consider the meta-analysed comparison as a
new statistical test in its own right. Moreover, the new hypothesis
test could be viewed as a type of sequential multiplicity, where the
comparison represents the first in a potential series of updates of a
systematic review and could therefore be considered analogous to
an added interim analysis in a clinical trial. Aside from these views,
and philosophically more straightforward, a systematic review may
introduce entirely new hypotheses to be tested. For example, new
subgroups may be tested, or the intervention effects were
measured but not tested in the initial trials.
Cochrane systematic reviews may contain more multiplicity
than non-Cochrane systematic reviews. TCC provides guidelines
for the writing of its reviews [18]. The editorial process is
extensive, providing support for authors throughout the develop-
ment of the peer reviewed protocol and the writing of the review.
Statistical editors, peer reviewers and consumers may all provide
input during the development of a protocol. It is possible that this
increased editorial involvement may limit the number of
comparisons planned, in an effort to minimise multiplicity. It is
also possible that intensive editorial involvement may increase the
number of planned comparisons, as the number of ideas for
relevant comparisons and sub-groups is increased. TCC also
encourages the grading of included trials based on their risk of bias
[21]. Many Cochrane authors will then do subgroup analyses
based on bias-control of included trials. Such subgroup analyses do
play an important role in assessing the validity of results, but they
also increase the number of comparisons made.
It seems likely that differences of opinion will exist about the
issue of statistical multiplicity in the context of systematic reviews.
Before the implications are properly considered and any solutions
implemented, the size of multiplicity in systematic reviews
deserves clarification. This study aimed to assist in that
clarification. The presence of multiplicity was quantified in a
population of Cochrane systematic reviews and in a population of
comparable non-Cochrane systematic reviews. The first aim was
to measure the overall quantity of statistical multiplicity within
this population. The second aim was to compare the quantity of
multiplicity in Cochrane reviews with that in comparable non-
Cochrane reviews.
Objectives
Primary outcome. Our primary outcome was the quantity
of statistical tests in systematic reviews and had two components.
First, we measured the quantity of statistical tests overall in our
sample of systematic reviews. Second, we tested the hypothesis that
the number of statistical tests is different in Cochrane and non-
Cochrane systematic reviews.
Secondary outcomes. We investigated four secondary
outcomes. We investigated the quantities overall in our sample
of systematic reviews and tested the hypotheses that the quantities
were different in Cochrane and non-Cochrane systematic reviews.
First, we aimed to quantify the proportion of systematic reviews
that clearly described a primary outcome. Methodological guides
for systematic review recommend selecting outcomes as principal
or primary [10,19,22]. We hypothesised that clear defining of a
primary outcome may be more common in either Cochrane or
non-Cochrane reviews.
Second, we aimed to quantify the number of statistical tests
done as part of a primary outcome in the systematic reviews. We
hypothesised that the quantity of statistical tests was being
controlled somewhat by defining a primary outcome and that
this control may be more evident in either Cochrane or non-
Cochrane reviews. Where no clear primary outcome was defined,
we considered it reasonable to consider all outcomes in a review as
part of the primary outcome.
Third, we aimed to quantify the proportion of systematic
reviews that used a risk of bias assessment as a reason for subgroup
analyses. We hypothesised that this reason for doing statistical tests
might be common in systematic reviews and that it may be more
common in either Cochrane or non-Cochrane reviews.
Fourth, we aimed to quantify the proportion of systematic
reviews that address the issue of statistical multiplicity in some way.
We hypothesised that few authors of systematic reviews are
currently addressing this issue and that these proportions may be
different in Cochrane and non-Cochrane reviews.
Methods
Selection of Reviews
We chose to examine the population of reviews that were
published in the Cochrane Anaesthesia Review Group (CARG).
We selected all the CARG reviews that that contained a meta-
analysis (as of October 2009). Each selected CARG review was
then matched with a comparable review from a paper journal. In
order to be included, the non-Cochrane review also needed to
contain a meta-analysis. We excluded reviews with any of the same
authors as those for the Cochrane counterpart.
We were conscious that the selection of the matched reviews
represented a potential limitation in our study. In a similar way to
a case-control study, our method for matching the Cochrane
reviews was susceptible to bias. In order to minimise this bias, we
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the non-Cochrane reviews.
We defined the intervention and population of each CARG
review before we commenced the selection process. We used these
definitions as our search terms. We reviewed the following search
engines looking for the best possible match: MEDLINE,
EMBASE, CENTRAL, CINAHL, Web of Science, IndMED
and KoreaMED. We didn’t apply any language restrictions.
Figure 1 shows how we selected the non-Cochrane reviews.
Data Extraction
We extracted the following data from each systematic review:
1. the number of statistical tests performed
2. whether a primary outcome was quoted (defined as a clear
statement in the methods section clarifying that one or more of
the outcomes in the review had been considered as of ‘primary’
importance)
3. the number of statistical tests performed as part of the primary
outcome
4. whether it was clear exactly how many statistical tests had been
done
5. whether subgroup analyses based on risk of bias assessment had
been done
6. whether the issue of statistical multiplicity had been addressed
in some way
In measuring the number of statistical tests done, we aimed to
measure the number of meta-analysed comparisons actually
performed in these reviews. Therefore, the measurements were
taken from the results sections in the papers. We attempted to
clarify the number of statistical tests done based on the
information provided in the published paper. This attempt
included reading any supplementary information referred to in
the text. We did not contact the authors of any reviews. When it
was impossible to clearly measure the number of comparisons,
we made estimates based on the information provided. For
example, when a paper stated that subgroup analyses were done
using four categories of risk of bias in included trials (but gave no
further information), we estimated that an extra two tests were
done for any meta-analysed comparison with greater than four
trials.
Meta-analysts can use either a random-effects or a fixed-effect
model for each statistical test. When both techniques were used
and reported, we did not count these repeated tests as extra tests.
The repeated tests are performed using the same data, and we felt
that it was reasonable to consider this repeat as a re-structure of
the same toss of the dice. Similarly, we did not count different
effect measures (of the same outcome), nor any investigations of
heterogeneity. Our aim was the count the number of statistical
tests done as part of meta-analysis, so we didn’t count any
statistical test results presented from single studies.
Three investigators independently read and examined each
included review. Each investigator made a decision as to how
many comparisons were conducted as part of each systematic
review. The final figure was decided after discussion and consensus
between the three investigators. A full copy of the data that was
extracted for each systematic review can be found in Appendix S1.
Statistical analyses
Primary outcome. To compare whether the number of
statistical tests is different in Cochrane and non-Cochrane
systematic reviews, we presented the respective distributions
using box plots. The medians of the two groups were compared
using the paired Wilcoxin test (two-tailed), with a P-value and an
estimate of the 95% confidence interval for the difference between
medians.
We conducted three sensitivity analyses on the primary outcome,
in order to explore whether the methodology of our own
investigation had affected our result. First, we used only the pairs
of systematic reviews where the number of statistical tests was
assessed as clear by all three investigators. Second, we used only the
pairs that were successfully matched for the same intervention.
Third, we used only the pairs of systematic reviews that were
published within the same three years. The three sensitivity analyses
were performed using the paired Wilcoxin test (two-tailed).
Secondary Outcomes. For the numerical data, we
compared the differences in the medians using the paired
Wilcoxin test (two-tailed). For the categorical data, we compared
the differences in proportion using the Chi Squared test (two
tailed).
Figure 1. Selection of non-Cochrane reviews.
doi:10.1371/journal.pone.0028422.g001
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Selection of Reviews
At the time when we selected the reviews, the Cochrane
Anaesthesia Review Group (CARG) had 58 published systematic
reviews. 43 of these reviews contained a meta-analysis. The search
terms that we used to find the best matches for these 43 reviews are
in Appendix S2. We were able to match 35 (81%) CARG reviews
with non-Cochrane reviews investigating the same intervention.
The remainder (19%) were matched with non-Cochrane reviews
using the same population. For 33 (77%) of the matches, the non-
Cochrane review was published within three years of its Cochrane
counterpart. See Appendix S2 and S3 for the full details of the
selection process and the list of selected systematic reviews.
Primary Outcome 1 – The number of statistical tests in
this population of systematic reviews overall
Overall, the median number of statistical tests in this population
of systematic reviews was 10. The interquartile range was 6 to 18.
The highest number of statistical tests in one systematic review was
1872 [23] and the second highest was 98 [24]. Figure 2 is a box
plot showing the distribution of these data. This box plot excludes
the systematic review with the highest number [23], as it is such an
extreme outlier.
Primary Outcome 2 – The comparison between the
number of statistical tests in Cochrane and
non-Cochrane systematic reviews
Figure 3 compares the distributions of the number of statistical
tests in the Cochrane and non-Cochrane reviews (excluding the
Carlisle 2006). Table 1 shows the results of the statistical
comparison between the number of tests in the Cochrane and
non-Cochrane systematic reviews.
Secondary Outcomes
The results for the four secondary outcomes are summarised in
Table 2.
The two Cochrane reviews that addressed the issue of
multiplicity in some way were Afshari 2006 [25] and Perry 2008
[26]. In the first, trial sequential analysis was used in the analysis of
the primary outcome. This statistical technique aims to correct for
the increased type 1 error caused by the testing of sparse data and
the multiplicity resulting from repeated updates in a cumulative
meta-analysis [27]. In the second, the authors mention multiplicity
as a limitation in their discussion.
The three non-Cochrane reviews that address the issue of
multiplicity in some way were Block 2003 [24], Phan 2008 [28] and
Shah 2005 [29]. A Bonferroni correction was used in the first for a
primaryoutcome withmultiplemeasurementofpain.Inthesecond,
the authors mentioned in the discussion that if Bonferroni
correction had been used to adjust for multiple comparisons, the
p-values would have been larger. In the third, the effect measures
were combined using an empirical Bayes random-effects estimator.
Discussion
We examined a population of reviews looking at interventions
that fall under the inclusion description of CARG. In this
population, we found an overall median of 10 statistical tests in
each review, with an interquartile range of 6 to 18. Does this
number represent a relevant quantity of statistical multiplicity?
If 10 statistical tests are done, each using a P value of 0.05 (or
corresponding 95% confidence intervals) as the threshold for
Figure 2. Box plot showing the median, interquartile range and range of the distribution of the number of statistical tests in our
population of systematic reviews (excluding Carlisle 2006).
doi:10.1371/journal.pone.0028422.g002
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5%. How much larger depends on the correlation between the
comparisons and the validity of the underlying null hypotheses.
The experimental error rate (EER)=the probability of rejecting at
least one of k independent null hypotheses when in fact all are
true. EER is given by:
EER~1{ 1{a ðÞ
k
where k equals the number of independent comparisons and
a=the assigned type I error. The probability of rejecting at least
one of the 10 null hypotheses incorrectly (assuming that they are
all true) is 0.60 (12(120.05)
10). Without adjustment, therefore, if
all null hypotheses are in fact ‘true’, and all the comparisons are
independent, there is a 60% probability of finding at least one
falsely significant result in our primary outcome. While it is
possible that a group of 10 null hypotheses in a systematic review
may be in fact ‘true’, it would be rare that they were independent.
So, in practice, the risk of making a type 1 error, if 10 tests are
done, lies somewhere between 5% and 60%. For 50% of the
systematic reviews in our study that did more than 10 statistical
tests, the risk of making at least one type 1 error is even higher.
The interpretation of the risk of type 1 error depends, to an
extent, on the intent of the systematic review. If we aim to
maintain a risk of type 1 error of less than 5%, and to interpret
conclusion as definitive and a reason to guide patient treatment,
then the quantity of statistical multiplicity observed in this study is
indeed relevant. Alternatively, if we aim to explore possible effects
of an intervention, with the aim of guiding further discussion and
research, then the quantity of statistical multiplicity observed may
not be considered relevant.
The number of statistical tests was higher in the Cochrane
reviews than in the non-Cochrane reviews. The difference in
medians was 4 (95% CI 2.0–19.0, P-value 0.011). None of the
three sensitivity analyses altered the significance of our finding.
There are many explanations for why Cochrane reviews may have
more multiplicity. Moreover, this increase may represent meth-
odological trends that are positive. It may be that as we improve
Figure 3. Box plot showing the median, interquartile range and range of the distribution of the number of statistical tests in the
Cochrane and non-Cochrane reviews (excluding the Carlisle 2006).
doi:10.1371/journal.pone.0028422.g003
Table 1. Results - Primary Outcome – Number of statistical tests.
Median - Cochrane
reviews
Median - Non-Cochrane
reviews
Difference in median (95%
Confidence Interval) P-value
Total number of statistical tests 12 8 4 (2.0–19.0) 0.011
Sensitivity analysis 1
1 10.5 7.5 3 (2.0–19.0) 0.006
Sensitivity analysis 2
2 14 8 6 (2.5–20.5) 0.007
Sensitivity analysis 3
3 12.5 8.5 4 (2.0–21.0) 0.012
1Using only the reviews where the number of statistical tests was assessed as clear by all investigators involved in data extraction.
2Using only the reviews that were successfully matched for the same intervention.
3Using only the reviews that were matched with a review that was published within the same three years.
doi:10.1371/journal.pone.0028422.t001
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increase the multiplicity. For example, Cochrane encourages the
investigation of adverse events [30]. Such investigation is clearly
important, but also leads to an increase in the number of
outcomes. Similarly, Cochrane encourages sensitivity analyses
including studies with varying risks of bias [21]. Methodological
flaws in included studies can cause major systematic errors (‘bias’)
in the conclusions of systematic reviews [31,32]. Omitting all
studies with methodological flaws may limit the authors’ ability to
make any conclusion at all. The practice of investigating the effect
of risk of bias on the conclusions represents a good solution. Again,
however, this methodological approach increases the amount of
multiplicity. Our study explored one of these hypotheses as to why
Cochrane reviews may contain more multiplicity. Risk of bias was
used as a reason to conduct extra subgroup analyses in 42% (18/
43) of Cochrane reviews and 12 (28%) of non-Cochrane reviews
(difference in proportion 14% (95% CI28 to 36). These
differences certainly suggest a quantifiable reason as to why
Cochrane reviews contain more multiplicity than their non-
Cochrane counterparts.
Only 6% (5/86) of the systematic reviews addressed the issue of
multiplicity in some way [24–26,28,29], either by just mentioning
the issue or by implementing a statistical methodology that may
adjust for it. The purpose of this study was not to assess the
accuracy or appropriateness of how multiplicity issues are handled
in systematic reviews. That difficult task lies in the future. Rather,
we aimed to assess whether it was being considered at all. Our
finding shows that the issue of multiplicity is currently largely
ignored in systematic reviews of anaesthesiological interventions
and this omission seems equal in Cochrane and non-Cochrane
reviews.
Primary outcomes were clearly defined in 63% (27/43) of the
Cochrane reviews and 51% (22/43) of the non-Cochrane reviews
(difference in proportions 12%, 95% CI 211 to 35). When one or
more outcomes are identified as primary, it seems reasonable that
comparisons done as part of that definition can be considered
confirmatory and all other comparisons as exploratory. When no
primary outcome is defined, it seems reasonable that all
comparisons done are of equal importance and potentially
confirmatory. We therefore considered the quantity of multiplicity
within the primary outcome. When there was no primary outcome
defined, we considered all the comparisons in the review as being
‘part of the primary outcome’. If multiplicity is considered in this
way, then the quantity is predictably less (median of 6 overall, IQR
4 to 13). While not statistically significant, the trend for more
multiplicity in the Cochrane reviews remained, with a difference in
medians of 2, (95% CI 0 to 7.5). The increased use of primary
outcomes in Cochrane reviews did not equate with a decrease in
primary outcome multiplicity.
Strengths and Limitations
We chose the population of CARG reviews as we felt that
anesthesia research, with its particularly elusive outcome data,
benefits greatly from reliable conclusions in meta-analytic
systematic reviews. The process for matching was carefully
designed, in order to find the best possible match and to minimize
selection bias. Unfortunately, we were not able to match all of the
CARG reviews according to their intervention. Some of the
reviews were matched based on the population investigated. And
in those cases, the interventions were not always anaesthesiologi-
cal. The sensitivity analysis including only the reviews with a good
match did support our overall findings. So the inclusion of non-
anaesthesiological reviews is unlikely to alter the validity of our
conclusion.
The number of statistical tests reported is not necessarily the
same as the number of tests conducted. Unlike non-Cochrane
reviews, Cochrane reviews always have published protocols and no
word limit for the size of the review. It is possible that authors of
non-Cochrane reviews perform more comparisons than they
report. Such selective reporting leaves a reader unable to interpret
the effect of multiplicity. Certainly, the transparent reporting of
many comparisons is more informative than the selective reporting
of few. The transparency of Cochrane protocols may reduce the
risk of selective reporting. In the context of our study, selective
reporting of outcomes may have been greater in the non-
Cochrane reviews, limiting our ability to accurately compare the
quantity of multiplicity. However, with regard to the quantity of
statistical multiplicity overall, hidden selective reporting would
only result in the quantity of the multiplicity present being greater
than what we measured.
We only counted the number of comparisons made within
individual systematic reviews. Repeated looks and repetitive
testing of accumulating data, both from multiple meta-analyses
on the same topic and from updating of reviews, also increases the
risk of type 1 error and may lead to spurious conclusions
[20,27,33,34]. A quantification of sequential multiplicity is
warranted, but it has not been addressed in this study.
There was – of course - statistical multiplicity present in our own
study. We conducted four statistical tests as part of our primary
analysis. We considered the importance of the three sensitivity
analyses when we wrote the protocol for our study and decided
that the value that they added, testing the validity of our primary
outcome, justified the increased risk for type 1 error. Our study
was explorative in nature, and its conclusion will not guide medical
Table 2. Results for the secondary outcomes.
All Reviews
Cochrane
reviews
Non-Cochrane
reviews
Difference in proportions
(95% Confidence Interval) P-value
Proportion of systematic reviews
with a clear primary outcome
57%
(49/86)
63%
(27/43)
51%
(22/43)
Difference in proportions:
12% (211 to 35)
0.365
Number of statistical test done
as part of the primary outcome
median 6
(IQR 4.0 to 13.0)
median 8
(IQR 4.5 to 16.5)
median 6
(IQR 3.5 to 10.8)
Difference in medians:
2 (0 to 7.5)
0.066
Proportion of studies using risk of
bias as a reason for further analyses
35%
(30/86)
42%
(18/43)
28%
(12/43)
Difference in proportions:
14% (28t o3 6 )
0.256
Proportion of reviews in which
the issue of multiplicity was
addressed in some way
6%
(5/86)
5%
(2/43)
7%
(3/43)
Difference in proportions:
2% (214 to 10)
1.00
doi:10.1371/journal.pone.0028422.t002
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consideration of the effect of the multiplicity was most appropriate.
The four comparisons were not independent, and the P-values
were consistent and low. We therefore concluded that statistical
multiplicity is unlikely to have affected the validity of our primary
comparison.
Power, however, may have compromised this validity. With post
hoc review, our study was probably underpowered to discern a
median difference of 4 comparisons given the wide range of
statistical multiplicity found in this population of systematic
reviews. Lack of power can impact on the reliability of a
statistically significant result as much as it can on the reliability
of a non-statistically significant one; in any analysis, a statistically
significant finding before an adequate sample size has been
reached may be a chance finding [35,36]. It is most accurate
therefore to consider our primary outcome as a possible trend,
rather than a definitive difference.
Conclusion
The quantity median number of statistical tests in this sample of
systematic reviews was 10 (IQR 6 to 18). We found a higher
number of statistical tests in the Cochrane systematic reviews
compared with their non-Cochrane counterparts. The difference
in medians was 4 (95% CI 2.0–19.0, P-value 0.011). Many of the
reasons for the increase in multiplicity may be sound and represent
improved methodological approach and greater transparency.
However, an increase in multiplicity may also represent an
increased risk of spurious conclusions. Very few systematic
reviews, whether Cochrane or non-Cochrane, address the issue
of multiplicity. A consideration of this issue is required.
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